bpc-157 not approved by fda statement fda.gov Undercutting HHS Secretary Robert F. Kennedy Jr.'s FDA reviews BPC-157, TB-500 and

Consult your healthcare professional if pregnant, breastfeeding or taking medication

Enzymes (e.g., amylase, lipase) catalyze and speed up chemical reactions

TB-500 provides critical enhancement of cellular migration and epithelial coverage that drives wound closure, with research demonstrating that topical or intraperitoneal TB-500 administration increases reepithelialization by 42% over controls at 4 days post-wounding and 61% at 7 days, with treated wounds showing enhanced contraction (at least 11% more than controls by day 7) and superior architectural organization

Location of Injection Sites With subcutaneous injections, drugs are delivered into the fatty tissue underneath your skin